10X Genomics, Inc.

10X Genomics, Inc. has achieved a new 52-week high, reflecting substantial growth in its stock price over the past year. With a market capitalization of USD 2,489 million, the company operates in a rapidly evolving biotechnology sector, despite currently facing financial challenges such as negative return on equity.

10X Genomics, Inc. has achieved a new 52-week high, reflecting significant growth over the past year. The company has outperformed the S&P 500, despite operating at a loss. Key financial metrics highlight its market capitalization and position within the biotechnology sector, emphasizing its growth potential.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. With a market capitalization of USD 2,489 million, the company has shown resilience despite being unprofitable, as indicated by its price-to-book ratio and unique financial structure.

10X Genomics, Inc. has achieved a new 52-week high, reflecting significant growth over the past year. Despite being unprofitable, the company maintains a market capitalization of USD 2,489 million. Key financial metrics reveal a price-to-book ratio of 3.13 and a negative return on equity of -10.80%.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a substantial increase in its stock price over the past year, significantly outpacing the S&P 500. With a market capitalization of USD 2,489 million, the company operates in a competitive biotechnology sector, despite currently reporting losses.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. With a market capitalization of approximately USD 2,489 million, the company has shown resilience despite losses, indicating a notable recovery in the competitive biotechnology sector.

10X Genomics, Inc. has seen a notable rise in stock performance, reflecting strong financial metrics, including a significant year-over-year increase. The company has reported positive results for five consecutive quarters, with impressive operating cash flow and a low debt-equity ratio, positioning it favorably in the market.

10X Genomics, Inc. has seen a notable rise in its stock price, achieving an 11.72% increase on June 15, 2026. The company has outperformed the S&P 500 over the past month and year, with strong operating cash flow and a low debt-equity ratio, indicating a solid financial position.

10X Genomics, Inc. saw a significant stock decline today, contrasting with the broader market's performance. Despite this, the company has achieved a remarkable annual return and consistent positive results over the past five quarters. High institutional ownership reflects strong investor confidence, though concerns about stock volatility persist.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. With a market capitalization of USD 2,132 million, the company operates in a competitive biotechnology sector, showcasing its potential despite being loss-making and not offering dividends.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a strong performance over the past year with a 33.41% gain. The company, with a market capitalization of USD 2,132 million, showcases a unique financial structure and continues to evolve within the competitive biotechnology sector.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. The company has seen a notable performance rise over the past year, with a market capitalization of USD 2,132 million. Despite ongoing losses, it continues to focus on growth and innovation in biotechnology.

10X Genomics, Inc. has experienced notable stock performance, with significant gains over various time frames, including a 215.91% increase over the past year. The company has reported strong financial results, including a record operating cash flow and a low debt-equity ratio, indicating a solid financial position.

10X Genomics, Inc. has achieved a new 52-week high, reflecting strong performance over the past year. The company, with a market capitalization of USD 2,132 million, is positioned in the small-cap sector. Despite losses, it maintains a notable price-to-book ratio and a unique financial structure.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. The company, with a market capitalization of USD 2,132 million, has seen a 17.58% performance rise over the past year, despite being loss-making and not offering dividends.

10X Genomics, Inc. has recently revised its evaluation amid current market dynamics. The stock is priced at $25.24, reflecting a notable annual performance with a 214.32% return. Technical indicators present a mixed outlook, while the company has shown significant volatility over the past year.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a notable performance with a 14.29% gain over the past year. Despite this progress, the company remains unprofitable, with a negative return on equity and no dividends offered, highlighting ongoing financial challenges.

10X Genomics, Inc. has recently undergone an evaluation revision amid current market dynamics. The company’s stock is priced at $23.00, reflecting a notable annual performance with a 165.28% return. Technical indicators present a mixed outlook, highlighting the company's volatility and the need for continued performance monitoring.

10X Genomics, Inc. has shown strong market performance, with notable gains over the past month and year, significantly outperforming the S&P 500. The company boasts solid financial metrics, including a robust operating cash flow and a high level of institutional holdings, reflecting investor confidence.